Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust relief from symptoms of depression in treatment-refractory depressed patients. Previous studies suggest that ketamine’s antidepressant properties involve enhancement of dopamine (DA) neurotransmission. Ketamine is rapidly metabolized to (2S,6S)- and (2R,6R)-hydroxynorketamine (HNK), which have antidepressant actions independent of N-methyl-d-aspartate glutamate receptor inhibition. These antidepressant actions of (2S,6S;2R,6R)-HNK, or other metabolites, as well as ketamine’s side effects, including abuse potential, may be related to direct effects on components of the dopaminergic (DAergic) system. Here, brain and blood distribution/clearance...
Subanesthetic rather than anesthetic doses are thought to bring the rapid antidepressant effects of ...
Major depressive disorder is the greatest burden of developed countries in the context of morbidity ...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust ...
Ketamine acts primarily by blocking the N-methyl-D-aspartate (NMDA) receptor at the phencyclidine si...
Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate receptor. It has recently been ...
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepre...
Since the therapeutic treatment of depression is far from being satisfactory, new therapeutic strate...
Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently available...
Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-...
Clinically used antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), aid only a...
Major depressive disorder afflicts ~16 percent of the world population at some point in their lives....
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
The prevailing hypothesis of ketamine’s unique antidepressant effects implicates N-methyl-d-aspartat...
The small molecule ketamine has generated much interest due to its rapid antidepressant effects. Des...
Subanesthetic rather than anesthetic doses are thought to bring the rapid antidepressant effects of ...
Major depressive disorder is the greatest burden of developed countries in the context of morbidity ...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...
Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust ...
Ketamine acts primarily by blocking the N-methyl-D-aspartate (NMDA) receptor at the phencyclidine si...
Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate receptor. It has recently been ...
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepre...
Since the therapeutic treatment of depression is far from being satisfactory, new therapeutic strate...
Fewer than 50% of all patients with major depressive disorder (MDD) treated with currently available...
Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-Methyl-D-...
Clinically used antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), aid only a...
Major depressive disorder afflicts ~16 percent of the world population at some point in their lives....
Major depressive disorder (MDD) is a devitalizing psychiatric condition with a lifetime prevalence o...
The prevailing hypothesis of ketamine’s unique antidepressant effects implicates N-methyl-d-aspartat...
The small molecule ketamine has generated much interest due to its rapid antidepressant effects. Des...
Subanesthetic rather than anesthetic doses are thought to bring the rapid antidepressant effects of ...
Major depressive disorder is the greatest burden of developed countries in the context of morbidity ...
Introduction: Increasing preclinical and clinical evidence underscores the role of glutamate in the ...